Back

Effect of sacubitril/valsartan and SGLT2 inhibitors on echocardiographic response and clinical outcomes after cardiac resynchronization therapy: insights from a real-world cohort

28 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Devices and heart failure Cardiac Resynchronisation Therapy (CRT) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Isabel Martins Moreira

Hospital Center of Tras-os-Montes and Alto Douro, Vila Real (Portugal)

4 More presentations in this session

Presentation thumbnail
The long term impact of home based cardiac rehabilitation protocols on heart failure patients
Associate Professor R. Kallel (Gabes, TN)
Abstract Slides Video
Presentation thumbnail
Effects of inspiratory muscle training for urban patients with chronic heart failure: a randomized controlled trial
Doctor A. Hattakitpanitchakul (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
A “LOT” better option? Assessing the response of left bundle branch-optimized pacing therapy in patients with poor response to cardiac resynchronization therapy with a pacemaker
Doctor D. Nair (Jonesboro, US)
Presentation thumbnail
Association of non-severe aortic stenosis with left ventricular reverse remodeling and clinical outcomes after cardiac resynchronisation therapy
Doctor M. Ishiyama (Tsu, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Devices and heart failure

The Event

Event poster

ESC Congress 2026

28 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of sacubitril/valsartan and SGLT2 inhibitors on echocardiographic response and clinical outcomes after cardiac resynchronization therapy: insights from a real-world cohort
10 May 2026
thumbnail
Congress Presentation
Treatment gradients across the left ventricular ejection fraction spectrum in ambulatory and acute heart failure: a multinational registry analysis
29 August 2026
thumbnail
Congress Presentation
Incremental benefit of sodium–glucose cotransporter 2 inhibitor and mineralocorticoid receptor antagonist therapy in HFpEF with moderate mitral regurgitation: 24-month ambulatory cohort study
29 August 2026
thumbnail
Congress Presentation
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors across heart failure phenotypes
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources